http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2712443-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3737a761c266a7f98dccd8c9f5b5490e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D285-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-433 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D285-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2018-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9d0e894f7a9b68229aa9c36ecbddd82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d47f2ee0f976f192e35e10977749ac4 |
| publicationDate | 2020-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2712443-C1 |
| titleOfInvention | Cocrystalline form of 1-[5-(4-chlorophenylamino)-1,2,4-thiadiazol-3-yl]-propan-2-ol |
| abstract | FIELD: chemistry.SUBSTANCE: invention relates to a co-crystalline form of 1-[5-(4-chlorophenylamino)-1,2,4-thiadiazol-3-yl]-propan-2-ol with oxalic acid, where the molar ratio of 1-[5-(4-chlorophenylamino)-1,2,4-thiadiazol-3-yl]-propan-2-ol with oxalic acid is 2:1, having an endothermic peak of 150 to 170 °C according to measurement data using differential scanning calorimetry, having peaks at angle 2θ(°) 6.5, 13.2, 14.3, 14.9, 16.5, 16.7, 18.7, 19.4, 19.7, 20.0, 20.7, 22.1, 23.3, 23.7, 24.8 according to X-ray powder diffraction measurement data having characteristic vibration frequencies 3442, 2973, 1643, 1493 , 1335, 1268, 1128, 1096, 1066, 941, 820, 744 cmaccording to infrared spectroscopy.EFFECT: co-crystalline form of 1-[5-(4-chlorophenylamino)-1,2,4-thiadiazol-3-yl]-propan-2-ol with oxalic acid is suitable for use in pharmaceutical industry as a component of a pharmaceutical preparation for treating various neurodegenerative diseases, including in therapy of Alzheimer's disease, with simultaneous increase of solubility.1 cl, 8 dwg, 2 ex |
| priorityDate | 2018-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.